Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Cymabay Therapeutics (CBAY)

Cymabay Therapeutics (CBAY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 451,210
  • Shares Outstanding, K 68,887
  • Annual Sales, $ 0 K
  • Annual Income, $ -102,810 K
  • 60-Month Beta 1.72
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.70

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.16
  • Number of Estimates 7
  • High Estimate -0.11
  • Low Estimate -0.19
  • Prior Year -0.38
  • Growth Rate Est. (year over year) +57.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.41 +24.39%
on 09/04/20
7.06 -4.67%
on 09/17/20
-0.05 (-0.74%)
since 08/18/20
3-Month
3.16 +112.97%
on 07/10/20
7.09 -5.08%
on 08/10/20
+3.07 (+83.88%)
since 06/18/20
52-Week
1.21 +456.20%
on 03/18/20
7.09 -5.08%
on 08/10/20
+1.12 (+19.96%)
since 09/18/19

Most Recent Stories

More News
CymaBay Therapeutics to Present at Upcoming Investor Conferences

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management...

CBAY : 6.62 (+1.07%)
CymaBay Therapeutics Presents Positive Final Results From 52-Week Phase 2 Study in Primary Biliary Cholangitis at The Digital International Liver Congress(TM) 2020

-- Self-reported pruritus improved at one year for patients in highest categories of baseline itch

CBAY : 6.62 (+1.07%)
CymaBay Therapeutics Announces Presentations During The Digital International Liver Congress(TM) 2020

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced...

CBAY : 6.62 (+1.07%)
CymaBay Reports Second Quarter 2020 Financial Results and Provides Corporate Update

FDA lifts all clinical holds on seladelpar

CBAY : 6.62 (+1.07%)
CymaBay Therapeutics to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it...

CBAY : 6.62 (+1.07%)
Thinking about buying stock in CymaBay Therapeutics, Trevena Inc, Co-Diagnostics, Plug Power, or Aurora Cannabis?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CBAY, TRVN, CODX, PLUG, and ACB.

ACB : 6.86 (-0.44%)
ACB.TO : 9.06 (-2.48%)
CBAY : 6.62 (+1.07%)
TRVN : 2.24 (+0.90%)
CymaBay Announces Positive Topline Results from ENHANCE for Seladelpar in Patients with Primary Biliary Cholangitis

-- Conference call today at 8:00 a.m. ET

CBAY : 6.62 (+1.07%)
CymaBay Therapeutics Presents Data at Digestive Disease Week 2020 Online Education

Data from previously completed open-label phase 2 study supports potential for seladelpar to improve pruritus (itching) in patients with PBC

CBAY : 6.62 (+1.07%)
Is the Options Market Predicting a Spike in CymaBay (CBAY) Stock?

Investors need to pay close attention to CymaBay (CBAY) stock based on the movements in the options market lately.

CBAY : 6.62 (+1.07%)
Notice of Change of Location of Annual Meeting of Stockholders to be Held on June 23, 2020

CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that, due...

CBAY : 6.62 (+1.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade CBAY with:

Business Summary

CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based...

See More

Key Turning Points

2nd Resistance Point 7.38
1st Resistance Point 6.96
Last Price 6.62
1st Support Level 6.23
2nd Support Level 5.92

See More

52-Week High 7.09
Last Price 6.62
Fibonacci 61.8% 4.84
Fibonacci 50% 4.15
Fibonacci 38.2% 3.46
52-Week Low 1.21

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar